Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:RVMD News 8 January 2026 - 26 January 2026

Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

Revolution Medicines shares fell 1.8% to $116.51 in early Monday trading, retreating from last week’s highs after reports of ongoing Merck acquisition talks valuing the company at up to $32 billion. Truist maintained its Buy rating but kept its price target at $99, below the current price. Investors await the company’s presentation at the J.P. Morgan Healthcare Conference later Monday.
12 January 2026
··
Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck shares fell 0.4% to $110.53 Friday as reports surfaced of talks to buy Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped 10.7% on the speculation. The Wall Street Journal and Financial Times said the deal would be among the largest pre-commercial biotech acquisitions. Investors await updates at the JPMorgan Healthcare Conference on Monday.
11 January 2026
···
Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

Revolution Medicines shares jumped 10.7% to $118.64 Friday amid reports Merck is in talks to acquire the company for up to $32 billion, according to the Financial Times. Trading volume hit 20.8 million shares. AbbVie denied it was in discussions after an earlier report, sending Revolution’s stock down 11.5% after hours. The FDA granted Breakthrough Therapy status to Revolution’s lung cancer drug candidate.
11 January 2026
··
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck shares fell 0.4% to $110.53 Friday after reports it is in talks to acquire Revolution Medicines for $28–32 billion. Revolution shares jumped in after-hours trading. The Financial Times said negotiations are ongoing, with no final deal yet. Investors are watching Merck’s appearance at the J.P. Morgan Healthcare Conference on Jan. 12.
10 January 2026
··
Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday

Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday

Revolution Medicines shares surged 10.7% to $118.64 Friday after reports that Merck is in talks for a $28–32 billion takeover. The FDA granted Breakthrough Therapy status to its lung cancer drug zoldonrasib. Insider filings show the CFO and COO sold shares earlier in the week under pre-arranged plans. Revolution denied rumors of a separate AbbVie bid.
10 January 2026
·
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck shares fell 0.4% to $110.53 after reports it is in talks to acquire Revolution Medicines for up to $32 billion. The company faces new scrutiny over its Gardasil and RotaTeq vaccines after U.S. policy changes, with analysts estimating a $2 billion annual revenue impact. Wolfe Research upgraded Merck, citing progress on a subcutaneous version of Keytruda.
10 January 2026
····
Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Revolution Medicines shares surged 10.7% to $118.64 in after-hours trading Friday after the Financial Times reported Merck is in advanced talks to acquire the company for $28 billion to $32 billion. The move follows the FDA granting Breakthrough Therapy designation to Revolution’s zoldonrasib for KRAS G12D-mutated lung cancer. Investors await Revolution’s Jan. 12 conference appearance for updates.
9 January 2026
··
Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines shares rose 4.3% to $112.00 Friday after reports that Merck is in talks to buy the company for up to $32 billion. The FDA granted Breakthrough Therapy designation to Revolution’s KRAS-targeting lung cancer drug this week. AbbVie denied involvement in any deal. Revolution declined to comment on the takeover speculation.
9 January 2026
··
Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck shares rose 0.4% to $111.41 Friday after a report said it is in talks to buy Revolution Medicines for $28–32 billion. Revolution shares jumped 16% in extended trading. Merck just completed a $221.50-per-share tender offer for Cidara Therapeutics and said the deal will raise 2026 R&D expense by $9 billion. Analysts warned U.S. vaccine policy changes could cut Merck revenue by $2 billion annually.
9 January 2026
···
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie shares fell 3.7% to $224.84 Thursday after the company denied takeover talks with Revolution Medicines and flagged a $1.3 billion fourth-quarter charge tied to R&D and milestone payments. AbbVie trimmed its 2025 profit forecast, setting adjusted earnings at $9.90 to $9.94 per share. Revolution Medicines dropped 5.5%. Wolfe Research downgraded AbbVie, citing limited upside.
8 January 2026
··
Revolution Medicines (RVMD) stock slips in premarket as AbbVie denies takeover talks, deal buzz lingers

Revolution Medicines (RVMD) stock slips in premarket as AbbVie denies takeover talks, deal buzz lingers

Revolution Medicines shares dropped 9.8% to $92.60 premarket after AbbVie denied takeover talks, erasing gains from a rumor-fueled surge. AbbVie’s denial followed a Wall Street Journal report of advanced deal discussions. A Form 144 filing showed officer Jack Lee Anders notified a proposed sale of 10,000 shares. CEO Mark Goldsmith is scheduled to present at the J.P. Morgan Healthcare Conference on Jan. 12.
8 January 2026
1 2

Stock Market Today

BBAI stock jumps 16% into BigBear.ai share-vote week — what to watch next

BBAI stock jumps 16% into BigBear.ai share-vote week — what to watch next

7 February 2026
New York, Feb 7, 2026, 08:52 EST — Market closed. BigBear.ai Holdings, Inc (NYSE: BBAI) shares jumped 15.7% on Friday to close at $4.72, a sharp bounce that put the small-cap AI and defense contractor back on traders’ screens heading into the new week. (StockAnalysis) The move matters now because BigBear.ai is closing in on a shareholder vote that would let it roughly double the number of shares it is allowed to issue — a step that can make it easier to raise cash, pay for deals, or grant stock awards, but can also dilute existing holders. The company has
American Airlines stock jumps nearly 8% as airlines rally — what to watch next week

American Airlines stock jumps nearly 8% as airlines rally — what to watch next week

7 February 2026
American Airlines shares jumped 7.6% to $15.24 Friday, rebounding with a broad rally that sent the Dow past 50,000 for the first time. Investors are watching the carrier’s battle with United at Chicago O’Hare, where a summer capacity surge could trigger a fare war. American also announced new Philadelphia–Porto service for 2027 and launched a centennial inflight menu.
Apple stock price ends week higher as Dow hits 50,000; jobs and CPI loom next

Apple stock price ends week higher as Dow hits 50,000; jobs and CPI loom next

7 February 2026
Apple closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. The S&P 500 jumped 1.97% and the Nasdaq rose 2.18% as chipmakers rallied, while Amazon fell 5.6% on higher capex guidance. Investors await U.S. jobs data Feb. 11 and CPI Feb. 13. Apple’s next dividend is $0.26 per share, payable Feb. 12.
Go toTop